Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1. (2020)

First Author: Marsh S
Attributed to:  Advanced peptide-oligonucleotide therapy for Myotonic Dystrophy Type 1 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ymthe.2020.10.005

PubMed Identifier: 33171139

Publication URI: http://europepmc.org/abstract/MED/33171139

Type: Journal Article/Review

Volume: 28

Parent Publication: Molecular therapy : the journal of the American Society of Gene Therapy

Issue: 12

ISSN: 1525-0016